U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07643870) titled 'Human ADME Study of [14C]-AZD1390' on Dec. 18, 2025.
Brief Summary: This is a Phase I, multicentre, single-dose, open-label study to assess the absorption, distribution, metabolism, and excretion of [14C]-AZD1390.
Study Start Date: June 30
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Malignancies
Intervention:
DRUG: AZD1390
single dose
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AstraZeneca
Disclaimer: Curated by HT Syndication....